Biohit Oyj B (BIOBV)

Currency in EUR
2.370
-0.050(-2.07%)
Closed·
Trading near 52-week Low
BIOBV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.3502.420
52 wk Range
2.3503.780
Key Statistics
Prev. Close
2.37
Open
2.42
Day's Range
2.35-2.42
52 wk Range
2.35-3.78
Volume
10.71K
Average Volume (3m)
12.05K
1-Year Change
-17.7083%
Book Value / Share
0.98
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIOBV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.500
Upside
+47.68%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company offers GastroPanel quick test NT, a rapid and quantitative immunochromatographic test for the detection of Helicobacter pylori and atrophic gastritis; GastroPanel test, a blood test for diagnosis of the function and structure of stomach mucosa; GastroSoft, a software application designed to assist clinicians and general practitioners in interpreting GastroPanel test results; and GP Reader NT for the quantitative determination of various analytes in human samples. It also provides BIOHIT active B12 (HoloTC) test, BIOHIT total 25OH vitamin D test, and BIOHIT Calprotectin; BIOHIT ColonView quick test for detection of fecal occult blood (FOB) in stool samples; BIOHIT Celiac quick test, a qualitative in vitro immunochromatographic test aiding in diagnosis of celiac disease; BIOHIT H. pylori UFT300 and H.pylori tests for the diagnosis of H,pylori infection; lactose intolerance quick test kit; and Gluten Immunogenic Peptides test. In addition, it offers Acetium acetaldehyde binding products, such as the Acetium lozenge to help quit smoking and Acetium capsule for the protection of the stomach. Further, the company provides monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. Additionally, it offers BIOHIT FAEX sample system for the collection and handling of stool samples. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.

Employees
46
Market
Finland

Compare BIOBV to Peers and Sector

Metrics to compare
BIOBV
Peers
Sector
Relationship
P/E Ratio
13.6x5.9x−0.5x
PEG Ratio
2.75−0.100.00
Price/Book
2.5x1.8x2.6x
Price / LTM Sales
2.3x1.5x3.1x
Upside (Analyst Target)
44.6%47.7%55.6%
Fair Value Upside
Unlock19.2%8.6%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.500
(+47.68% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Feb 11, 2026
EPS / Forecast
0.12 / 0.07
Revenue / Forecast
8.3M / --
EPS Revisions
Last 90 days

BIOBV Income Statement

People Also Watch

35.30
HARVIA
-1.12%
18.00
REG1V
+0.90%
10.24
MEKKO
-2.85%
34.45
OLVAS
-0.43%
123.0
AFRY
-1.36%

FAQ

What Is the Biohit Oyj B (BIOBV) Stock Price Today?

The Biohit Oyj B stock price today is 2.370 EUR.

What Stock Exchange Does Biohit Oyj B Trade On?

Biohit Oyj B is listed and trades on the Helsinki Stock Exchange.

What Is the Stock Symbol for Biohit Oyj B?

The stock symbol for Biohit Oyj B is "BIOBV."

What Is the Biohit Oyj B Market Cap?

As of today, Biohit Oyj B market cap is 36.020M EUR.

What Is Biohit Oyj B's Earnings Per Share (TTM)?

The Biohit Oyj B EPS (TTM) is 0.178.

From a Technical Analysis Perspective, Is BIOBV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Biohit Oyj B Stock Split?

Biohit Oyj B has split 0 times.

How Many Employees Does Biohit Oyj B Have?

Biohit Oyj B has 46 employees.

What is the current trading status of Biohit Oyj B (BIOBV)?

As of Mar 20, 2026, Biohit Oyj B (BIOBV) is trading at a price of 2.370 EUR, with a previous close of 2.370 EUR. The stock has fluctuated within a day range of 2.350 EUR to 2.420 EUR, while its 52-week range spans from 2.350 EUR to 3.780 EUR.

What Is Biohit Oyj B (BIOBV) Price Target According to Analysts?

The average 12-month price target for Biohit Oyj B is 3.500 EUR, with a high estimate of 3.5 EUR and a low estimate of 3.5 EUR. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +47.68% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.